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Murine embryonic stem (ES) cells are pluripotent, but significant
functional engraftment does not occur when they are introduced
into the liver. However, here we demonstrate that functional liver
engraftment does occur if the ES cells (from strain 129 mice) are
first differentiated in vitro for 7 days in the presence of FGF.
Strikingly, when these differentiated cells, termed putative
endodermal precursors (PEPs), were injected into their livers, two
of six C57BL6 and four of eight BALBc factor IX (F-IX)-deficient
mice survived for >7 days, even though the recipients were of a
different strain and, in the case of the BALBc recipients, had a
complete MHC mismatch. F-IX was detected in all six of the
PEP-injected survivors. Two mice subsequently died of causes
unrelated to F-IX; the others survived until death at 38 or 115 days
after the transplantation. No uninjected control F-IX-deficient mice
survived for >7 days. Large confluent regions of sinusoidal PEP
engraftment were demonstrated by immunofluorescence in the
long-term BALBc survivors. The PEP engraftment was not associ-
ated with detectable cell fusion, and the transplantation was
accompanied with only a low incidence of teratoma formation.
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Embryonic stem (ES) cells can differentiate into most celltypes, thus leading to intense interest in their potential for
therapeutic applications (1). Despite this interest, problems have
arisen in translating the potential of ES-derived cells into
therapeutic strategies. The dominant problems have been lack of
function, allograft rejection, and teratoma formation (1–4). Yet,
the therapeutic potential for ES-derived cells remains substan-
tial. Thus, if ES-derived cells could be successfully engrafted
within the hepatic parenchyma, they could serve as gene re-
placement vectors for correcting liver-based genetic defects such
as hemophilia A and B. Cells with hepatocyte phenotypes have
been derived from ES cells in vitro, using strategies involving
isolating cells from dissociated embryoid bodies (5). However,
achieving function with these cells has proven to be difficult (3,
6, 7), and no reports have been published of ES-derived cells
persisting with function across allogeneic barriers.
We have previously demonstrated that murine ES cells re-
moved from feeders can rapidly respond to in vitro inductive
signals from chick cardiac mesoderm, resulting in differentiation
into cells with a putative endodermal phenotype (8), thereby
mimicking the transcriptional regulation for endodermal com-
petence found in development (9–13). In our current experi-
ments, we removed ES cells from their feeder layer and stimu-
lated them with acidic FGF (100 gml) for 7 days. We find that
cells differentiated in this manner, termed putative endodermal
precursors (PEPs), can engraft the liver and function in vivo in
histocompatibility mismatched recipients sufficiently well
enough to allow long-term survival of factor IX (F-IX)-deficient
mice. No obvious histological evidence of allograft rejection was
apparent in the recipient livers, and no alloantibodies were
detectable. Teratoma formation was infrequent.
Materials and Methods
Enhanced GFP-Expressing ES Cells. To facilitate the identification of
successful engraftment, we used PEPs differentiated from a
murine ES cell line that constitutively expresses a single-copy
transgene driven by the ubiquitously expressed -actin promoter
(8) encoding for an enhanced GFP (Stratagene) and localizes to
the nucleus. This ES cell line is derived from a strain 129P2Ola
mouse. Cells were maintained in murine embryonic fibroblast
feeder layers that produce leukemic inhibitory factor. To ensure
viability and pluripotency, ES cell media were changed daily, and
ES cells were passed every 2–3 days. Their karyotypes were
checked at intervals.
ES Cell Culture. ES cell propagation media consisted of high-
glucose DMEM (Sigma) supplemented with 15% FBS (Sigma)
0.1 mM 2-mercaptoethanol (Sigma)100 units/ml penicillin100
g/ml streptomycin (GIBCO).
ES Cell Differentiation. Propagation media were supplemented
with 100 ngml acidic FGF (Sigma). The cells were removed
from their feeders and plated in P35 collagen-coated plates. The
media were carefully changed daily, and the cells were allowed
to obtain an 50% density. When the cells were ready for
transplantation or analysis, they were removed from the plates
with 0.05% trypsin (Sigma)0.02% EDTA4Na in PBS, counted,
and stained for viability with Trypan blue.
F-IX ELISA. The ELISA was performed as described by Gui et al.
(14) with the following modifications. Both the capture and
detection antibodies were sheep anti-mouse specific for F-IX (a
kind gift of Affinity Biologicals, Ancaster, ON, Canada) with the
detection antibody covalently linked to horseradish peroxidase.
Purified mouse F-IX (produced and purified in the laboratory of
D. Stafford, University of North Carolina) was used as the
standard.
Quantitative RT-PCR. Real-time fluorescent quantitative PCR was
performed by using an ABI PRISM 7700 (Applied Biosystems).
The sequences of the oligonucleotides are listed in Supporting
Text, which is published as supporting information on the PNAS
web site.
Fluorescent Stereomicroscopy. To initially identify the engraft-
ment, fresh liver explants were examined with a stereomicro-
scope (MZ16FA, Leica Microsystems, Wetzlar, Germany) using
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a GFP2 long-pass filter (100447084, Leica Microsystems) to
detect the presence of GFP-positive cells.
Procedure Modifications for F-IX-Deficient Mice. The F-IX knockout
mice used in our transplant studies were first confirmed to be
F-IX-negative by PCR genotyping, and a day 0 F-IX baseline was
collected. To perform the partial hepatectomy, the mice were
given 100 unitskg recombinant human F-IX (15), both by
intramuscular and s.c. injection after anesthesia, and another s.c.
dose 4 h after the operation. At the time when the GFP-PEP
injections were performed, on postoperative day 3, the intra-
muscular and s.c. doses of human F-IX were repeated. F-IX
levels were assessed by ELISA on the plasma (14) 4, 7, and 10
days after injection and on a weekly basis thereafter. Recombi-
nant human F-IX (stock concentration; 575 gml) was from the
laboratory of D. Stafford.
Partial Hepatectomy. Adult mice (C.129P2F9tm1DwsFre,
B6.129P2tm1DwsFre) [F-IX, BALBc and C57BL6] 6–15 weeks
of age were obtained from the laboratory of D.W.S. Wild-type
BALBc and C57BL6 mice were obtained from The Jackson
Laboratory. Mice were kept in a Department of Laboratory
Animal Medicine facility and were watered and fed regular chow
ad libitum. Mice were anesthetized with an s.c. injection of
ketaminexylazene mixture (60 mgkg ketamine and 6 mgkg
xylazene). Once under anesthesia, the thoracic and abdominal
surfaces were shaved by using appropriate animal clippers (Oster
Golden A5), and the shaved area was decontaminated by
applying betadine, followed by 70% ethanol. Once the mouse
was anesthetized, the abdominal cavity was entered through a
2-cm incision starting just below the sternum and traveling
straight down the abdominal wall. The median liver lobes (left
and right) and the large left lateral lobe were isolated, tied off
with 3-0 ties, and removed. After removing the lobes, the
abdomen was closed with 4-0 prolene or silk suture. Before the
abdominal wall was closed, 1 ml of room temperature PBS was
placed in the abdomen. Mice then recovered in a clean, dry,
warm cage under a warming lamp until they were mobile. Mice
were given a 0.1 gkg i.p. dose of buprenorphine every 12 h after
surgery for 2 days and were monitored closely thereafter.
Hepatic Injection of ES-Derived Cells. PEPs (1  106) were sus-
pended in 100 l of PBS with 1% FBS and kept at 4°C for 30
min. The mice were anesthetized with an s.c. injection of
ketaminexylazene mixture (60 mgkg ketamine and 6 mgkg
xylazene) by using a 28- or 31-gauge syringe. Once under
anesthesia, a small incision was created below the right costal
margin, and the liver lobe was delivered into view with a cotton
swab. The cell suspension was injected directly into the paren-
chyma. Postoperative pain management was performed as
above.
Tissue Processing. To further characterize cell engraftment,
treated mice that showed significant levels of F-IX by ELISA
were anesthetized with 60 mgkg ketamine and 6 mgkg xyla-
zene and perfused transcardially with PBS, followed by 4%
paraformaldehyde. The liver was removed and fixed overnight in
4% paraformaldehyde in PBS, transferred to 30% sucrose in
PBS overnight, and then mounted in OCT compound (Tissue-
Tek, Sakura Finetek, no. 4583) for quick-freezing. The liver
samples were sliced into 10-m-thick sections with a cryostat
(Leica Microsystems, Bannockburn, IL), mounted onto clean
superfrostplus slides, air-dried, and stored at 80°C until
processing. Tissue samples from positive (wild types) and neg-
ative (nontransplanted F-IX) samples were obtained and
processed identically to the experimental samples.
Histology. Samples were fixed in 4% paraformaldehyde overnight
and transferred into 30% sucrose for a minimum of 24 h.
Samples were then placed in a cryomold (Tissue-Tek, 25  20 
5 mm) with OCT compound (Tissue Tek, no. 4583), frozen at
80° for a minimum of 24 h, and processed by cryosectioning in
Leica no. CM 3050 S cryostat. Cryosections of 10- to 12-m
thickness were rehydrated in PBS, mounted with aqueous
mounting medium (DAKO), and examined by fluorescence
microscopy for the presence of GFP cells.
Immunofluorescence. Slides with tissue cryosections processed as
above were washed twice in PBS, permeabilized, and blocked
against nonspecific binding in blocking buffer (5% normal
serum2% BSA0.1% Triton X-100 in PBS) for 30 min. Samples
were then incubated with sheep anti-rat F-IX antibody (Haema-
tologic Technologies, Essex Junction, VT) for 90 min at room
temperature at a final dilution of 1:200 in blocking buffer. After
the incubation, samples were washed three times with PBS-
0.05% Triton X-100, followed by incubation with Texas red-
labeled anti-sheep IG (Fab2) IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA) diluted 1:200 in blocking buffer
for 30 min. After three washings in PBS-0.1% Triton X-100,
samples were incubated with rabbit polyclonal GFP antibody
conjugated to Alexa Fluor 488 (Molecular Probes) for 1 h at
room temperature (1:400 dilution in blocking buffer) after three
washings with PBS-0.1% Triton X-100 and mounted with
Vectashield mounting media (Vector Laboratories). Processed
slides were examined under a Zeiss Axiovert S100 fluorescent
microscope, and representative slides were further analyzed by
confocal laser-scanning microscopy performed on a Zeiss LSM5
Pascal microscope (Thornwood, NY).
Laser-Capture Microdissection (LCM). Slides containing frozen sec-
tions were placed on the stage of an Arcturus Pix-Cell II LCM
system (Arcturus Engineering, Mountain View, CA). Either a
standard CapSure or a new HS LCM cap was placed on the
section. Desired areas of tissue were maneuvered under the
target beam, and the IR laser was fired to melt the special plastic
membrane from the cap into the tissue. After all desired areas
were shot in this way, the cap was lifted off the tissue, bringing
with it only the selected tissue. Fragments of loose tissue were
removed from the cap by pressing the cap onto the adhesive
surface of a new PostIt (3M, St. Paul) note. The cap was then
placed into an Eppendorf tube containing extraction buffer.
Images were made before capture, after capture, and of the cap
containing captured material.
Antidonor Antibody Testing. Serum from graft recipient mice was
tested for antibodies reactive to strain 129 spleen cells because
PEPs were derived from strain 129 and share MHC with 129
splenocytes. Serum from BALBc mice engrafted with PEPs was
diluted and incubated with 129 target cells. Cells were subse-
quently washed and incubated with goat anti-mouse Ig. Cells
were washed and run on a flow cytometer (FACSCalibur, B D
Biosciences, Mountain View, CA), and the data were analyzed
by using SUMMIT software (Cytomation, Fort Collins, CO). A
polyclonal antiserum, (AXB10.D2), F1 anti-B10.A (5R), was
used as a positive control.
Results
Directed in Vitro Differentiation of ES Cells.We stimulated ES cells,
removed from their feeder layer, with acidic FGF (100 gml)
for 7 days, and we found by quantitative RT-PCR (16) that the
cells display a statistically significant reduction in mRNA of Oct
4 (P  0.01), and an increase in mRNA of -fetoprotein (P 
0.01), GATA4 (P  0.05), albumin, (P  0.05), FoxA2 (P 
0.06), and Sox 17 (P  0.06) (Fig. 4, which is published as
supporting information on the PNAS web site). These molecular











changes coincide with dramatic morphologic changes and the
appearance of large cells with distinctive growth patterns (Fig. 1
A and B). We refer to the resulting cells as PEPs.
Cellular Transplantation of PEPs. To optimize the potential condi-
tions for PEPs to engraft, we initially chose to partially hepate-
ctomize the recipient mice. Numerous studies have explored
possible routes of delivering cells for engraftment in the hepatic
parenchyma (17). We performed preliminary injection studies
(data not shown) that showed that direct injection of PEPs into
the liver resulted in their dispersal throughout the parenchymal
vasculature. This method was chosen as providing a direct
delivery of PEPs to the intended engraftment location. When
fresh explanted liver tissue is screened by 3D fluorescent mi-
croscopy, the exogenous GFP-ES-derived cells are easily visu-
alized and distinguished from the endogenous hepatic paren-
chyma, which autof luoresces, allowing for immediate and
accurate detection of engraftment. Fig. 1 C and D illustrates
typical results 20 days after injecting strain 129 (H2b)-derived
PEPs into a C57BL6 recipient, also (H2b). The GFP-PEP
hepatic engraftment displays a consistent pattern with the
GFP-PEP cells coursing along the sinusoids within the space of
Disse. Engraftment comparable to that shown in Fig. 1 C and D
occurred in 10 of 19 mice (52%) injected with PEPs versus 0 of
14 mice injected with 1  106 undifferentiated ES cells (2 
10.6; P  0.01).
Having observed robust engraftment in a MHC type (H2b)
recipient, we asked whether GFP-PEP could be transplanted
across a major MHC barrier. Using the same in vitro and in vivo
protocol as above, we partially hepatectomized BALBc (H2d)
mice, which are strain- and MHC-mismatched to the cells from
which the PEPs, strain 129 (H2b), are derived. The PEPs were
then injected as described, and this injection resulted in engraft-
ment in 5 of 10 (50%) of the recipients 10 days after the
GFP-PEP injection. We saw no histologic evidence of rejection
in these grafts.
We tested for the possibility that cell fusion was the dominant
mechanism of hepatic engraftment by analyzing the genetic
composition of GFP-fluorescing cells in the hepatic parenchyma.
LCM was used to isolate GFP-expressing cells, and quantitative
DNA PCR was used to quantify the genomic DNA contribution
from engrafted cells versus wild-type cells in the GFP-
f luorescing areas of parenchyma. The results (Fig. 5, which is
published as supporting information on the PNAS web site) show
no detectable colocalization of wild-type DNA with the GFP
DNA in the engraftment areas, thereby excluding cell fusion as
the dominant mechanism of the PEP hepatic engraftment and
function in our experiments.
Teratoma formation is a major concern when using ES-
derived cells for cellular engraftment. Including all of our data
for 46 C57BL6 mice and 18 BALBc mice transplanted with
PEPs, we find an overall teratoma rate of 6.2% (4 of 64 mice).
Three of the 46 injected C57BL6 mice developed teratoma, and
none of them were engrafted mice. Of 18 BALBc mice injected,
an encapsulated teratoma developed in one engrafted mouse,
adjacent to the liver but not associated directly with the en-
grafted regions of the liver.
Engrafted GFP-PEP Produce F-IX. Initial experiments with C57BL6
F-IX knockout mice, having only minor histocompatibility dif-
ferences from the strain 129-derived PEPs, showed that, of the
four mice surviving hepatectomy and injection, two survived
beyond 7 days. Mouse no. 1 in Fig. 2 survived for 88 days after
injection, achieving a F-IX level of 340 ngml, which is 10% of
normal. This mouse was 18 months old at the time of death, and
postmortem examination revealed no obvious cause of death or
pathology related to the PEP engraftment. (The lifespan of a
F-IX-deficient mouse is 18–24 months.) Mouse no. 2 in Fig. 2
Fig. 1. In vitro and in vivo postengraftment morphology of PEPs. (A) Undifferentiated ES cells on feeder layer in vitro. (B) Cell appearance after differentiation
with FGF (100 ngml) in media for 7 days in vitro (magnification 200x). (C and D) Engraftment images 20 days after PEP injection into liver. With GFP filter only
(C), image reveals engraftment of GFP PEPs; with phase overlay (D), image reveals GFP engraftment into hepatic parenchyma (magnification; 63).
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showed typical hepatic histological engraftment with GFP-PEPs
and substantial plasma concentrations of F-IX by day 10, but it
died during anesthesia for blood drawing on day 10. We also
subjected 18 F-IX-deficient mice to partial hepatectomies and
human F-IX injections, but without subsequent PEP injections;
none of these mice survived 7 days. We conclude that the
injected PEPs provide a survival advantage in this model.
Based on the preceding experiments demonstrating that
strain 129-derived GFP-PEPs can engraft across a complete
MHC and non-MHC barrier, we subjected BALBc F-IX-
deficient mice to PEP transplantation with or without preced-
ing hepatectomy. No immunosuppressive therapy was admin-
istered. Four of six mice survived surgery and showed
continuous F-IX expression from 38 to 115 days. One mouse
(mouse no. 3 in Fig. 2) had received hepatectomy before
injection, and three mice (mice numbered 4–6 in Fig. 2)
received PEP injection without hepatectomy. Mouse no. 3 was
intentionally killed on day 38 because of the emergence of an
abdominal mass adjacent to the liver capsule. Mice numbered
4–6 were killed on day 115. No evidence of neoplasm was
observed in these mice at autopsy or histological sectioning of
the explanted livers. GFP mRNA was detectable throughout
the livers by PCR. Fig. 3 demonstrates large cords of GFP-
positive cells within the hepatic parenchyma, from mouse no.
5 in Fig. 2, that colocalize F-IX by immunof luorescence.
Because of this successful engraftment across an MHC barrier,
we examined serum from the BALBc recipients for 129J-
reactive antibodies by f low cytometry at 7 and 115 days after
transfer. We found no detectable antibodies at either time
directed at 129 or BALBc spleen cells. Normal serum from
BALBc mice was also nonreactive.
Discussion
Our study demonstrates that ES-derived cells with early
endodermal characteristics engraft, persist, and function in the
liver. The cells we have described as PEPs have five features that
make them highly promising in this setting. First, PEPs are
obtained directly from ES cells by culture with FGF as an
inductive stimulus. Second, when injected into the liver paren-
chyma, PEPs are able to engraft robustly and restore wild-type
hepatocellular function in F-IX-deficient mice. F-IX-deficient
mice (18, 19) have a phenotype that is similar to hemophilia B
in humans, characterized by a severe bleeding diathesis caused
by absence of F-IX protein (20, 21). F-IX has a short half-life
requiring continuous replacement, and, consequently, any sub-
stantial production of mouse F-IX in the deficient mice indicates
hepatocyte function derived from the engrafted PEPs. Third,
PEPs engraft and persist across a complete mismatched MHC
barrier. Fourth, PEPs exhibit only a low incidence of teratoma
formation. Fifth, PEPs do not require host liver injury or
regeneration to engraft and function.
Each of these five features requires further investigation.
For example, it is important to characterize the changes that
occur during the FGF inductive phase, which are demonstrably
sufficient to produce transplantable cells. The occurrence of
teratoma in some recipients also requires further study. Our
experience suggests that teratoma formation is a separate
event from that leading to functional PEP engraftment. Thus,
in the three cases, it occurred in the mice that had no liver
engraftment, and, in the one of 21 mice that had the described
sinusoidal engraftment pattern, the teratoma was extra-
hepatic. If this suggestion is correct, then purification of the
differentiated PEPs before injection should reduce this com-
plication. In this regard, it is also important to recall that strain
129 mice, from which the ES cells are derived, are notable for
an unusually high incidence of spontaneous teratoma (22).
Several strategies are available that may decrease or eliminate
teratoma formation. One strategy is to use ES cells from
another mouse strain that is less prone to spontaneous tera-
tomas. A second strategy is based on our observation of a
sharply increased expression of MHC class I antigens on the ES
cells during their in vitro differentiation. A sorting strategy
based on this marker should exclude any undifferentiated ES
cells likely to give rise to teratomas.
The appearance of PEP engraftment in liver parenchyma
illustrated here is different from that seen in other reports
describing ES-derived cell engraftment in the liver (3, 6). We
suspect that the cells possess an intrinsic rate of proliferation but
that this rate subsides over time, as judged by the histologic
appearance of the engraftment at 4 months; this phenomenon
requires further investigation.
Cell fusion has been suggested as the dominant mechanism
by which stem cells engraft in the liver, and numerous studies
have shown that stem cells can fuse with the native hepatocytes
and adopt a liver-specific phenotype (23, 24). These fusion
events, however, have been in engraftment that involves
individual cells in the liver parenchyma, rather than the diffuse
engraftment of hundreds of contiguous cells in islands as seen
in our model. Furthermore, pluripotent fractions of umbilical
cord blood can engraft into the liver with low rates of fusion
(25, 26) Although fusion as a primary mechanism of the
large-scale engraftment seen in our model is excluded, more
detailed future studies are required to see whether a low rate
of fusion could be present.
Other questions include whether the biologic benefit we
observe with PEPs is limited to deficiency states or can be
generalized for the management of other hepatic diseases.
Elucidation of factors important for engraftment, such as adhe-
sion molecule expression, proliferation rates, and metabolism,
Fig. 2. Plasma F-IX concentrations over time in C57BL6 and BALBc F-IX-
deficient mice after engraftment with PEPs as determined by ELISA.











will be critical. Whether hepatic engraftment with PEPs results
in temporary or long-term allogeneic chimerism or induces
tolerance to other allografts, as has been reported in another
stem cell transplant model (27), also requires further study. Our
observation of allogeneic graft survival is especially intriguing,
given that mature allogeneic hepatocytes are vigorously rejected
via CD4 and CD8 (nonclassical) pathways when transplanted
into the liver, (28, 29). Even though the immunological mech-
anisms leading to graft persistence are not known, our finding
that PEP engraftment occurs across a major MHC barrier is very
encouraging for the use of allogeneic ES stem cells for treating
human disease.
In summary, our demonstration of functional, persistent he-
patic engraftment with PEPs serves as a proof of principle that
directly differentiated ES cells are likely to have clinical rele-
vance for the replacement of hepatic function. With concen-
trated efforts directed toward solving the various critical ques-
tions that we have discussed, it seems possible that effective
clinical use of in vitro-differentiated ES cells may become a
reality.
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